X4 Pharmaceuticals, Inc. has entered into a significant purchase agreement with Lincoln Park Capital Fund, LLC, granting the company the right to sell up to $40 million worth of its common stock to Lincoln Park. The agreement, effective from June 23, 2025, spans a 24-month term during which X4 Pharmaceuticals can control the timing and amount of stock sales. A registration rights agreement was also established to facilitate this process. As part of the arrangement, X4 issued 137,099 shares to Lincoln Park as a commitment fee, though it will not receive cash proceeds from this issuance. The company plans to use any proceeds from the stock sales for working capital and general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.